Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bioconjugate
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Nona Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Nona Biosciences will integrate GeneQuantum's exclusive and innovative iLDC and iGDC platforms, with its Harbour Mice® platform and cutting-edge technologies, to advance the early discovery of next-generation bioconjugates.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 13, 2023
Lead Product(s) : Bioconjugate
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Nona Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, GeneQuantum will provide InxMed with its globally leading technologies in site-specific glycan conjugation, stable linker small molecule technology, and intelligent continuous conjugation production platform for developing innovative...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 17, 2023
Details : Under the collaboration, GeneQuantum and Aimed Bio aims to jointly develop up to five new antibody-drug conjugate drugs to address unmet clinical needs for patients with severe brain diseases.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 06, 2023
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Technology
Study Phase : Discovery
Recipient : Thousand Oaks Biologics
Deal Size : $28.3 million
Deal Type : Partnership
Details : Under the partnership, GQ will leverage TOBio's expertise in CMC and commercial manufacturing to advance its pharmaceutical research on antibody-drug conjugate (ADC) products by using its innovative conjugation technology.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 22, 2023
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Technology
Highest Development Status : Discovery
Recipient : Thousand Oaks Biologics
Deal Size : $28.3 million
Deal Type : Partnership
Lead Product(s) : GQ1010
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Pyramid Bio
Deal Size : $1,020.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Pyramid Biosciences will develop and commercialize GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting TROP2, worldwide except for Greater China, using GeneQuantum's proprietary technology.
Brand Name : GQ1010
Molecule Type : Large molecule
Upfront Cash : $20.0 million
April 13, 2023
Lead Product(s) : GQ1010
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Pyramid Bio
Deal Size : $1,020.0 million
Deal Type : Licensing Agreement
Lead Product(s) : GQ1005
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GQ1005, is a HER2 targeting ADC with an excellent bystander killing effect, and the stable linker technology have demonstrated the advantages through several IND enabled drug candidates.
Brand Name : GQ1005
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 15, 2022
Lead Product(s) : GQ1005
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AMB302
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Aimed Bio
Deal Size : Undisclosed
Deal Type : Collaboration
GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate
Details : The collaborating ADC is a first-in-class asset AMB302, with highly differentiated antibody against a unique target, a stable linker design and a novel payload with a strong by-stander killing effect.
Brand Name : AMB302
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 19, 2022
Lead Product(s) : AMB302
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Aimed Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : GQ1007
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : BrighGene Biomedical
Deal Size : Undisclosed
Deal Type : Collaboration
Gene Quantum and Brigh Gene Sign Agreement for Development of Antibody Immune Agonist Conjugates
Details : Both companies signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007. GQ1007 is a new type of antibody-drug conjugate which has achieves strong and lasting anti-tumor effect, overcomes the low response rate of PD-1 antibo...
Brand Name : GQ1007
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 05, 2021
Lead Product(s) : GQ1007
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : BrighGene Biomedical
Deal Size : Undisclosed
Deal Type : Collaboration
GeneQuantum Raises Hundreds of Millions RMB in Series C Funding
Details : GQ1001 is an antibody drug conjugate (ADC) that is currently in global multi-center clinical trial development for treatment of HER2+ solid tumor. GQ1001 was synthesized by site-specific conjugation of toxin DM1 to trastuzumab.
Brand Name : GQ1001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 19, 2021
LOOKING FOR A SUPPLIER?